Prime Medicine, Inc.
PRME
$1.39
$0.1512.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 19.50% | 5.08% | -20.90% | 30.29% | -29.45% |
| Total Depreciation and Amortization | 10.21% | 1.30% | 16.96% | 5.45% | 0.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.35% | -38.90% | 90.47% | 12.63% | -23.08% |
| Change in Net Operating Assets | 186.13% | 459.57% | 84.23% | -308.38% | 502.33% |
| Cash from Operations | 162.69% | 43.04% | 32.81% | -54.36% | -12.00% |
| Capital Expenditure | -40.25% | 32.86% | 18.16% | -26.30% | 36.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.05% | 486.85% | 125.34% | -180.48% | 223.71% |
| Cash from Investing | -4.15% | 630.23% | 118.62% | -189.70% | 209.31% |
| Total Debt Issued | -- | -- | -200.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -- | 77,903.61% | -38.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | -100.00% | 109,937.14% | -99.98% | 80,996.39% | -38.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.47% | 263.23% | -173.33% | 2,304.95% | 96.89% |